Wave life sciences reports second quarter 2021 financial results and provides business update

Dosing underway in focus-c9 clinical trial of wve-004 in c9-als / c9-ftd – first oligonucleotide using pn backbone chemistry modifications in clinical study

WVE Ratings Summary

WVE Quant Ranking